Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
As many as 37 percent of all prostate cancers are detected late or in advanced stages in the UK, finds a new report from the charity Orchid. The report suggests that most of these cancers are detected at stages 3 and 4. Statistics show that nearly 47,000 men are diagnosed with prostate cancer annually and 11,000 succumb to the disease each year.
UCLA researchers have discovered that a combination of high doses of radiotherapy and hormonal therapy provides the best chance of decreasing the mortality rate in men with aggressive prostate cancer.
Myriad Genetics, Inc. today announced that a comparative analysis of commercially available prognostic breast cancer tests in patients with early-stage breast cancer has been published in JAMA Oncology.
An international group of clinicians and scientists representing the Clinical Pharmacogenetics Implementation Consortium published the first-ever clinical practice guideline for using CYP2D6 genotype to guide tamoxifen therapy in Clinical Pharmacology and Therapeutics.
A $1 million grant from Gateway for Cancer Research will help Rutgers Cancer Institute of New Jersey Urologic Oncology Chief Isaac Yi Kim, MD, PhD, MBA evaluate the impact of surgically removing the prostate in men with metastatic prostate cancer in the United States and Asia.
A new study conducted at the University College London, UK, found a new marker that has the capacity to help diagnose fatal breast cancer up to one year earlier than existing methods.
Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced new results from two studies with EndoPredict are being featured at the 2017 San Antonio Breast Cancer Symposium in San Antonio, Texas.
According to a latest study, several factors are responsible for the differences in the survival statistics of the non-elderly women with breast cancer. For example in 2012, the health reports had revealed that black women have a 43% higher risk of death when affected with breast cancer compared to their white counterparts.
Researchers have finally found the genetic targets that could be used for treatment and development of new drugs in patients who are resistant to chemotherapy. These patients who are resistant to chemotherapy are most likely to have triple negative breast cancer which is the most aggressive form of breast cancer. The study appeared in the latest issue of the journal Cell Metabolism.
According to a research conducted at the University of Jyväskylä, estrogen acts as a regulator of muscle energy metabolism and muscle cell viability. Menopause leads to the cessation of ovarian estrogen production concurrent to the deterioration of muscle function.
Patients with high risk prostate cancer starting long-term hormone therapy may benefit from two new treatments, according to late-breaking results from the STAMPEDE trial presented at the ESMO 2017 Congress in Madrid.
There has been much debate regarding the utility of prostate cancer screening in reducing the rates of deaths due to this cancer among men. While the ERSPC (European Randomized Study of Screening for Prostate Cancer) suggests that screening reduced prostate cancer deaths, the PLCO (Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial) found that regular screening does not reduce the cancer death rates in prostate cancer. Researchers thus looked at the actual picture as to which of these – ERSPC or PLCO are correct.
The Southeast's first comprehensive cancer treatment program at the University of Alabama at Birmingham takes patient care to the next level by improving the lives of women affected by or at risk for ovarian cancer.
NewYork-Presbyterian and Weill Cornell Medicine have begun the first clinical trial in the United States that uses a small molecule to treat men with progressive prostate cancer that has spread beyond the prostate and is no longer responding to hormonal therapy.
New research indicates that dietary soy products are safe and even beneficial for women diagnosed with breast cancer. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help resolve controversies over soy's potential link to breast cancer outcomes.
For women with a rare subtype of epithelial ovarian or peritoneum cancer, known as low-grade serous carcinoma, hormone maintenance therapy may significantly improve survival, according to a new study from researchers at The University of Texas MD Anderson Cancer Center.
Postmenopausal estrogen-based hormone therapy lasting longer than ten years was associated with a decreased risk of Alzheimer's disease in a large study carried out at the University of Eastern Finland.
Taking one-fourth the standard dose of a widely used drug for prostate cancer with a low-fat breakfast can be as effective - and four times less expensive - as taking the standard dose as recommended: on an empty stomach.
Only about 35 percent of precancerous breast lesions morph into cancer if untreated, but physicians cannot identify which lesions are potentially dangerous.
New data presented at the 2016 San Antonio Breast Cancer Symposium (SABCS) demonstrate that analyzing tumor biology with the Oncotype DX test can identify patients unlikely to benefit from chemotherapy prior to breast cancer surgery (neoadjuvant setting) and guide treatment decisions without compromising outcomes.